Cancer-Killing virus paired with immunotherapy shows promise in sarcoma trial

NCT ID NCT03069378

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase 2 study tests a combination of two drugs—talimogene laherparepvec (T-VEC), a virus that attacks cancer cells, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in 41 adults with advanced sarcoma that has spread or cannot be removed by surgery. The main goal is to see how many patients' tumors shrink or disappear. The trial is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talimogene laherparepvec (T-VEC) and pembrolizumab
What this could lead to: If successful, this combination could offer a new treatment option for advanced sarcoma, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 41 participants. The combination may cause significant side effects, and results may not apply to all sarcoma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS ANGIOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epithelioid sarcoma myxofibrosarcoma Neoplasm Metastasis sarcoma skin angiosarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS ANGIOSARCOMA EPITHELIOID SARCOMA SARCOMA

Contacts and locations

Locations

Enable Medicine (Specimen Analysis Only)

Menlo Park, California, 94025, United States
MD Anderson Cancer Center (Data Analysis Only)

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States
Stanford University Medical Center

Stanford, California, 94305-5408, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.